<DOC>
	<DOCNO>NCT01484951</DOCNO>
	<brief_summary>The purpose study assess safety efficacy switch Azarga prior pharmacotherapy patient open-angle glaucoma .</brief_summary>
	<brief_title>AZARGA Transition Study Taiwan Patients With Uncontrolled Intraocular Pressure</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Clinical diagnosis ocular hypertension , primary openangle pigment dispersion glaucoma eye . Must stable regimen intraocular pressure ( IOP ) lower medication within one week screening/baseline visit . Must IOP 19 35 mmHg ( inclusive ) least one eye , would study eye , screen . Must willing discontinue use ocular hypotensive medication prior receive study medication entire course study . Must best correct visual acuity 6/60 ( 20/200 Snellen , 1.0 LogMAR ) good eye . Other protocoldefined inclusion criterion may apply . Known medical history allergy , hypersensitivity , poor tolerance component medication use study deem clinically significant opinion principal investigator . Any abnormality prevent reliable applanation tonometry either eye . Risk visual field visual acuity worsen consequence participate study , investigator 's best judgment . Pregnant lactating . Participation investigational study within 30 day screen visit . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Open-angle glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
	<keyword>Pigment dispersion glaucoma</keyword>
</DOC>